4 results on '"Wheatley, Keith"'
Search Results
2. Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
- Author
-
Defachelles AS, Bogart E, Casanova M, Merks JHM, Bisogno G, Calareso G, Gallego Melcon S, Gatz SA, Le Deley MC, McHugh K, Probst A, Rocourt N, van Rijn RR, Wheatley K, Minard-Colin V, and Chisholm JC
- Subjects
- Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols pharmacology, Child, Child, Preschool, Europe, Female, Humans, Infant, Infant, Newborn, Irinotecan pharmacology, Male, Middle Aged, Neoplasm Recurrence, Local, Rhabdomyosarcoma pathology, Temozolomide pharmacology, Vincristine pharmacology, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Irinotecan therapeutic use, Rhabdomyosarcoma drug therapy, Temozolomide therapeutic use, Vincristine therapeutic use
- Abstract
Purpose: The VIT-0910 trial was conducted to evaluate efficacy and safety of the vincristine-irinotecan combination with and without temozolomide (VIT and VI, respectively) in relapsed or refractory rhabdomyosarcoma (RMS)., Methods: In this randomized European phase II trial, patients age 0.5-50 years received 21-day cycles combining vincristine (1.5 mg/m
2 once a day on day 1 and day 8) and irinotecan (50 mg/m2 once a day from day 1 to day 5) with and without temozolomide (125 mg/m2 once a day from day 1 to day 5 and 150 mg/m2 once a day from cycle 2), until progression or unacceptable toxicity. The primary end point was objective response rate after two cycles. Secondary end points included best response, progression-free survival, overall survival, and adverse events. A Simon 2-stage design was initially planned to separately analyze 40 patients/arm. After amendment, the trial sample size was increased to 120 and a comparison between arms, adjusted for confounding factors, was added to the statistical plan (ClinicalTrials.gov, NCT01355445)., Results: Overall, 120 patients (60 per arm) were recruited in 37 European centers. The median age was 11 years (range, 0.75-45); 89% of patients had a relapsed RMS. The objective response rate was 44% (24 of 55 evaluable patients) for VIT versus 31% (18 of 58) for VI (adjusted odds ratio, 0.50; 95% CI, 0.22 to 1.12; P = .09). The VIT arm achieved significantly better overall survival (adjusted hazard ratio, 0.55; 95% CI, 0.35 to 0.84; P = .006) compared with VI, with consistent progression-free survival results (adj-hazard ratio, 0.68; 95% CI, 0.46 to 1.01; P = .059). Overall, patients experienced adverse events ≥ grade 3 more frequently with VIT than VI (98% v 78%, respectively; P = .009), including a significant excess of hematologic toxicity (81% v 61%; P = .025)., Conclusion: The addition of temozolomide to VI improved chemotherapy efficacy for patients with relapsed RMS, with manageable increase in toxicity. VIT is considered the new standard treatment in these patients in the European paediatric Soft Tissue Sarcoma Group and will be the control arm in the next randomized trial., Competing Interests: Michela CasanovaConsulting or Advisory Role: Roche, Bayer, BMS, AstraZenecaTravel, Accommodations, Expenses: Roche, Bayer Johannes H.M. MerksConsulting or Advisory Role: Bayer, GlaxoSmithKline Gianni BisognoConsulting or Advisory Role: Bayer, Roche, iQone healthcareTravel, Accommodations, Expenses: Jazz Pharmaceuticals Soledad Gallego MelconConsulting or Advisory Role: Loxo, EUSA Pharma, IQvia, Clinigen Group, BayerTravel, Accommodations, Expenses: Loxo Susanne Andrea GatzConsulting or Advisory Role: Tesaro, BayerTravel, Accommodations, Expenses: AstraZeneca Rick R. van RijnPatents, Royalties, Other Intellectual Property: Royalties from Springer and Thieme Keith WheatleyResearch Funding: Roche, Bio-Cancer Treatment International, EUSA Pharma, Bayer Véronique Minard-ColinResearch Funding: Roche/Genentech, Bristol Myers Squibb/Pfizer Julia C. ChisholmConsulting or Advisory Role: Roche, Bayer, Roche/Genentech, BayerNo other potential conflicts of interest were reported.- Published
- 2021
- Full Text
- View/download PDF
3. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.
- Author
-
Dirksen U, Brennan B, Le Deley MC, Cozic N, van den Berg H, Bhadri V, Brichard B, Claude L, Craft A, Amler S, Gaspar N, Gelderblom H, Goldsby R, Gorlick R, Grier HE, Guinbretiere JM, Hauser P, Hjorth L, Janeway K, Juergens H, Judson I, Krailo M, Kruseova J, Kuehne T, Ladenstein R, Lervat C, Lessnick SL, Lewis I, Linassier C, Marec-Berard P, Marina N, Morland B, Pacquement H, Paulussen M, Randall RL, Ranft A, Le Teuff G, Wheatley K, Whelan J, Womer R, Oberlin O, and Hawkins DS
- Subjects
- Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bone Neoplasms mortality, Bone Neoplasms pathology, Child, Child, Preschool, Disease Progression, Europe, Female, Humans, Infant, Lung Neoplasms mortality, Lung Neoplasms secondary, Male, Middle Aged, Neoplasm Recurrence, Local, Pneumonectomy, Progression-Free Survival, Radiotherapy, Adjuvant, Risk Assessment, Risk Factors, Sarcoma, Ewing mortality, Sarcoma, Ewing secondary, Time Factors, Transplantation, Autologous, Young Adult, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Bone Neoplasms therapy, Hematopoietic Stem Cell Transplantation adverse effects, Hematopoietic Stem Cell Transplantation mortality, Lung Neoplasms therapy, Neoadjuvant Therapy adverse effects, Neoadjuvant Therapy mortality, Sarcoma, Ewing therapy
- Abstract
Purpose: The R2Pulm trial was conducted to evaluate the effect of busulfan-melphalan high-dose chemotherapy with autologous stem-cell rescue (BuMel) without whole-lung irradiation (WLI) on event-free survival (main end point) and overall survival, compared with standard chemotherapy with WLI in Ewing sarcoma (ES) presenting with pulmonary and/or pleural metastases., Methods: From 2000 to 2015, we enrolled patients younger than 50 years of age with newly diagnosed ES and with only pulmonary or pleural metastases. Patients received chemotherapy with six courses of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) and one course of vincristine, dactinomycin, and ifosfamide (VAI) before either BuMel or seven courses of VAI and WLI (VAI plus WLI) by randomized assignment. The analysis was conducted as intention to treat. The estimates of the hazard ratio (HR), 95% CI, and P value were corrected for the three previous interim analyses by the inverse normal method., Results: Of 543 potentially eligible patients, 287 were randomly assigned to VAI plus WLI (n = 143) or BuMel (n = 144). Selected patients requiring radiotherapy to an axial primary site were excluded from randomization to avoid excess organ toxicity from interaction between radiotherapy and busulfan. Median follow-up was 8.1 years. We did not observe any significant difference in survival outcomes between treatment groups. Event-free survival was 50.6% versus 56.6% at 3 years and 43.1% versus 52.9% at 8 years, for VAI plus WLI and BuMel patients, respectively, resulting in an HR of 0.79 (95% CI, 0.56 to 1.10; P = .16). For overall survival, the HR was 1.00 (95% CI, 0.70 to 1.44; P = .99). Four patients died as a result of BuMel-related toxicity, and none died after VAI plus WLI. Significantly more patients in the BuMel arm experienced severe acute toxicities than in the VAI plus WLI arm., Conclusion: In ES with pulmonary or pleural metastases, there is no clear benefit from BuMel compared with conventional VAI plus WLI.
- Published
- 2019
- Full Text
- View/download PDF
4. Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial.
- Author
-
van den Berg H, Paulussen M, Le Teuff G, Judson I, Gelderblom H, Dirksen U, Brennan B, Whelan J, Ladenstein RL, Marec-Berard P, Kruseova J, Hjorth L, Kühne T, Brichard B, Wheatley K, Craft A, Juergens H, Gaspar N, and Le Deley MC
- Subjects
- Adolescent, Antineoplastic Agents, Alkylating adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bone Neoplasms pathology, Cyclophosphamide administration & dosage, Disease Progression, Disease-Free Survival, Doxorubicin administration & dosage, Drug Substitution, Europe, Female, Health Status Disparities, Humans, Ifosfamide administration & dosage, Male, Proportional Hazards Models, Risk Factors, Sarcoma, Ewing pathology, Sex Factors, Time Factors, Treatment Outcome, Vincristine administration & dosage, Antineoplastic Agents, Alkylating administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Bone Neoplasms drug therapy, Sarcoma, Ewing drug therapy
- Abstract
Background: Based on the randomised Euro-EWING99-R1 trial, vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide (VAI) in the treatment of standard-risk Ewing sarcoma. However some heterogeneity of treatment effect by gender was observed. The current exploratory study aimed at investigating the influence of gender on treatment efficacy and acute toxicity., Patients and Methods: Impact of gender on event-free survival (EFS), acute toxicity by course, switches between treatment arms and cumulative dose of alkylating agents was evaluated in multivariable models adjusted for age including terms to test for heterogeneity of treatment effect by gender. The analysis of the EFS was performed on the intention-to-treat population., Results: EFS did not significantly differ between the 509 males and 347 females (p=0.33), but an interaction in terms of efficacy was suspected between treatment and gender (p=0.058): VAC was associated with poorer EFS than VAI in males, hazard ratio (HR) (VAC/VAI)=1.37 [95% confidence interval (CI), 0.98-1.90], contrasting with HR=0.81 [95%CI, 0.53-1.24] in females. Severe toxicity was more frequent in females, whatever the toxicity type. Thirty patients switched from VAI to VAC (9/251 males, 4%, and 21/174 females, 12%) mostly due to renal toxicity, and three from VAC to VAI (2/258 males, 0.8%, and 1/173 females, 0.6%). A reduction of alkylating agent cumulative dose >20% was more frequent in females (15% versus 9%, p=0.005), with no major difference between VAC and VAI (10% versus 13%, p=0.15)., Conclusion: Differences of acute toxicity rate and cumulative doses of alkylating agents could not explain the marginal interaction observed in the Euro-EWING99-R1 trial data. Effects of gender-dependent polymorphism/activity of metabolic enzymes (e.g. known for CYP2B6) of ifosfamide versus cyclophosphamide should be explored. External data are required to further evaluate whether there is heterogeneity of alkylating agent effect by gender., Trial Numbers: NCT00987636 and EudraCT 2008-003658-13., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.